QLT Inc. (QLTI) To Delay Initiation of Phase IIa Atrigel/octreotide Program, Company to Save $1 Million in R&D
Tweet Send to a Friend
QLT Inc. (NASDAQ: QLTI) announced that it will delay the initiation of its Phase IIa Atrigel/octreotide program in acromegaly patients ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
